EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Catalysing tuberculosis elimination in Indonesia: Health economic and policy insights from the BPaL regimen

Abdullah Antaria iD, Heidy Agustina, Ratnawati Ratnawati, Sita Laksmi Andarini, Diah Handayani

PLOS One · 07.08.2026 · 21 (8) · e0351836

DOI: 10.1371/journal.pone.0351836 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 07.08.2026. Verfasst von Abdullah Antaria und 4 weiteren Autor:innen. Beteiligte Einrichtung: Health Polytechnic of the Ministry of Health Jakarta I, Cilandak, Jakarta Selatan. Indonesia. Hauptthemen laut MEDLINE: Antitubercular Agents, Tuberculosis, Multidrug-Resistant, Diarylquinolines. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Indonesia diagnoses roughly 24,000 multidrug-resistant tuberculosis (MDR-TB) cases each year, 8% of the world’s total. Conventional treatment runs 18–24 months, costs US$7,142–9,000 per patient, and succeeds in only 59% of cases. The WHO endorsed Bedaquiline-Pretomanid-Linezolid (BPaL) regimen has shown over 89% efficacy in controlled trials, but real-world health economic data from low- and middle-income countries remain scarce.

Methods

We conducted a retrospective cohort study of 84 patients with MDR-TB, rifampicin-resistant TB (RR-TB), or pre-extensively drug-resistant TB (pre-XDR-TB) treated at Persahabatan Hospital, Jakarta, between 2021 and 2024. We compared treatment success, costs, and operational metrics against historical controls from 2018–2020. Statistical methods included chi-square tests, multivariate logistic regression, and incremental cost-effectiveness ratio (ICER) calculations, with sensitivity analyses across ±20% cost and ±10% efficacy ranges.

Results

BPaL achieved 77.4% treatment success (65/84 patients) compared with 59% in historical controls (p < 0.01). Per-patient costs dropped 67%, from US$7,142–9,000 to US$2,310. The ICER was US$311.4 per additional treatment success. Hospital stays shortened by 60% (10 versus 25 days; p < 0.01), and adherence climbed from 70% to 95.2% (p < 0.01).

Conclusions

BPaL is effective, affordable, and ready to scale. Integrating it into Indonesia’s Jaminan Kesehatan Nasional (JKN) framework and expanding decentralised diagnostics could accelerate progress towards WHO End TB 2030 targets. Our findings offer a replicable model for other low- and middle-income settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsTuberculosis, Multidrug-ResistantDiarylquinolinesIndonesiaHumansRetrospective StudiesFemaleCost-Benefit AnalysisMaleAdultHealth PolicyCost-Effectiveness Analysis

Substanzen

Antitubercular AgentsDiarylquinolinesbedaquiline

Autor:innen und Institutionen

  • Health Polytechnic of the Ministry of Health Jakarta I, Cilandak, Jakarta Selatan. Indonesia.
  • Department of Respiratory Medicine, Faculty of Medicine, University of Indonesia, Persahabatan Hospital, Jakarta Timur, Jakarta, Indonesia.

ORCID-Profile: Abdullah Antaria

Zitieren

APA

Antaria, A., Agustina, H., Ratnawati, R., Andarini, S. L., & Handayani, D. (2026). Catalysing tuberculosis elimination in Indonesia: Health economic and policy insights from the BPaL regimen. PLOS One, 21(8), e0351836. https://doi.org/10.1371/journal.pone.0351836

Vancouver

Antaria A, Agustina H, Ratnawati R, Andarini SL, Handayani D. Catalysing tuberculosis elimination in Indonesia: Health economic and policy insights from the BPaL regimen. PLOS One. 2026;21(8):e0351836. doi:10.1371/journal.pone.0351836

BibTeX
@article{Antaria2026,
  author = {Antaria, Abdullah and Agustina, Heidy and Ratnawati, Ratnawati and Andarini, Sita Laksmi and Handayani, Diah},
  title = {Catalysing tuberculosis elimination in Indonesia: Health economic and policy insights from the BPaL regimen},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {8},
  pages = {e0351836},
  doi = {10.1371/journal.pone.0351836}
}
Kostenlos starten →